Positive DARRT-1 Data in Late-Stage Prostate Cancer
02 déc. 2019 09h00 HE
|
Noxopharm
Clinical responses point to the NOX66 DARRT treatment regimen as a potentially major new treatment option for men with late-stage prostate cancerPositive results trigger planning for proposed pivotal...
Noxopharm Announces Appointment of Chief Commercial Officer
06 nov. 2019 09h26 HE
|
Noxopharm
Noxopharm has appointed Mr Alexander Hunter as Chief Commercial OfficerMr Hunter is an experienced corporate finance and business executive with a background in high growth listed company operations...
Potential for Fundamental Change in the Treatment of Brain Cancer
18 oct. 2019 09h13 HE
|
Noxopharm
Noxopharm commences a research program pursuing a novel approach to the treatment of glioblastoma multiforme (GBM), the most common and aggressive form of brain cancerBased on recent international...
Further Data Review Shows Major Clinical Benefits From Veyonda®
30 sept. 2019 08h00 HE
|
Noxopharm
Comparative data shows Veyonda® significantly boosts the effectiveness of a promising new form of radiation therapy (177LuPSMA) in advanced prostate cancer177LuPSMA therapy is the subject of a recent...
Veyonda® and Radiotherapy Profiled at Key Oncology Meeting
17 sept. 2019 11h01 HE
|
Noxopharm
Research relating to Veyonda® in the treatment of advanced prostate cancer is to be included in a key Australian oncology meetingBoth Noxopharm and independent investigators have abstracts...
Media Statement Veyonda® Enhances Radiotherapy in Prostate Cancer Treatment Further Promising Results
28 août 2019 07h57 HE
|
Noxopharm
SYDNEY, Australia, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Noxopharm (ASX: NOX) (‘Noxopharm’ or the ‘Company’) today announced the interim three month results from the second part of the DARRT-1 study on...
Pre-Clinical Evidence Confirms Veyonda® Abscopal Effect
21 août 2019 08h12 HE
|
Noxopharm
Veyonda® is being developed as a transformative anti-cancer treatment (DARRT) in combination with radiotherapy to produce off-target responses known as an abscopal effectPre-clinical studies now...
Appendix 4C– June 2019 Quarter
29 juil. 2019 08h00 HE
|
Noxopharm
Positive results from two prostate cancer trialsPhase 2 trial design gaining momentumInvestigational New Drug Application to be submitted to FDA in Q3 2019Pipeline developing based on drug discovery...